Impact Analysis of Covid-19
The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.
Various laboratory techniques are utilized for disease diagnostics for identification of test samples such as blood and urine for identification and quantification of infective agents. Moreover, providing diagnosis based only on symptoms is challenging, as two or more diseases can exhibit similar symptoms, therefore diagnostic tests are utilized for confirmation of the disease. Diagnostic tests offers rapid and precise results, thereby saving time and provides physicians’ ample time for treatment.
Get FREE Sample PDF Including COVID-19 Impact Analysis: https://www.coherentmarketinsights.com/insight/request-pdf/1971
The global infectious disease diagnostics market is estimated to be valued at US$ 1,131.4 Mn, in terms of value in 2020 and is expected to reach US$ 1,841.2 Mn by the end of 2027.
Global Infectious Disease Diagnostics Market: Drivers
The increasing initiatives by organizations to address diagnostic challenges in emerging economies is expected to fuel growth of the global infectious disease diagnostics market over the forecast period. For instance, in January 2018, the Foundation for Innovative New Diagnostics entered into a collaboration with Becton, Dickinson, and Company (BD), Fondation Botnar, the Global Antibiotic Research & Development Partnership (GARDP), the Drugs for Neglected Diseases Initiative (DNDi), and the South African Medical Research Council (SAMRC) to address antimicrobial resistance (AMR) by accelerating the use of diagnostics.
Global Infectious Disease Diagnostics Market: Opportunities
Additionally, public and private initiatives to limit infectious diseases is the factor that is expected to offer lucrative growth opportunities for players in the market. For instance, Department of Health and Human Services announced a federal grant of US$ 750,000 to the city of Austin to help fight the spread of HIV/AIDS in Texas, U.S., in February 2020.
Global Infectious Disease Diagnostics Market: Restraints
However, low awareness and adoption of diagnostic services in emerging economies are the factors that are expected to hamper growth of the market over the forecast period. For instance, according to the Global AIDS UPDATE 2019 of UNAIDS, in Madagascar, Mauritius, and South Sudan, less than 25% of people living with HIV are aware of their status.
Among technique, cell cultures segment in the global infectious disease diagnostics market was valued at US$ 362.3 Mn in 2018, and is estimated to reach US$ 747.4 Mn by 2027, exhibiting a CAGR of 8.3% over the forecast period. The segment growth is attributed to the cell culture technique, where various types of infections can be diagnosed using cell culture, where, microbes are grown in a laboratory setting to identify the same.
Browse Press Release: https://bit.ly/31Vb3Sh
On the basis of disease indication, STDs segment accounted for major market share of 32.8%, in terms of value in the global infectious disease diagnostics market in 2018, followed by CNS infection, and respiratory infections, respectively. The growth of the segment is attributed to rising incidence of sexually transmitted disease, globally. Among 20 STDs, the most common STD’s include Gonorrhea, Chlamydia, Syphilis, Herpes, Hepatitis (HBV), and Human Immunodeficiency Virus (HIV). For instance, according to the Centers for Disease Control and Prevention (CDC), in 2016, 1,598,354 cases of Chlamydia trachomatis infection were reported in the U.S., corresponding to 497.3 cases per 100,000 in 2015.
On the basis of end user, diagnostic centers segment in the global infectious disease diagnostics market was valued at US$ 462.1 Mn in 2018 and is expected to reach US$ 958.7 Mn by 2027 exhibiting a CAGR of 8.5% over the forecast period. The segment growth is attributed to central diagnostic laboratories that are well equipped with latest diagnostic instruments, and have large resources to carry out multiple tests. Moreover, increasing number of tests are carried out in these centers on a daily basis, which is further expected to drive growth of the segment.
Additionally, limited specificity of diagnostic tests available for infectious diseases triggers the need for combined diagnosis, which includes multiple tests. The trend of diagnosing a disease through multiple tests is gaining popularity.
Among regions, North America is expected to witness significant growth over the forecast period, attributed to increasing healthcare expenditure. For instance, according to the Centers for Medicare & Medicaid Services (CMS), healthcare spending in the U.S. is estimated to grow at an average rate of 5.5% per year during 2018-2027, and to reach nearly US$ 6.0 trillion by 2027. However, the reimbursement scenario for diagnostic tests is comparatively low.
Global Infectious Disease Diagnostics Market: Competitive Landscape
Key players operating in the global infectious disease diagnostics market include Becton Dickinson & Company, Cepheid, Inc., Abbott Laboratories, BioMerieux SA, Hologic, Inc., Danaher Corporation, Thermo Fisher Scientific, Inc., Roche Diagnostics, Alera Inc., DiaSorin S.p.A., Quidel Corporation, and Bio-Rad Laboratories, Inc.
Global Infectious Disease Diagnostics Market: Key Developments
March 2020: Chembio Diagnostics, Inc., a point-of-care diagnostics company focused on infectious diseases, completed the technical feasibility phase for a potential companion/compatible diagnostic test in collaboration with Shire Human Genetic Therapies, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited
March 2020: GenMark Diagnostics, Inc., a manufacturer of automated, multiplex molecular diagnostic testing systems, submitted an Emergency Use Authorization to the U.S. Food and Drug Administration (FDA) for its ePlex SARS-CoV-2 Test
Apply Promo Code “CMIFIRST1000” And Get Instant Discount Of USD 1000
Buy Now this Premium Report to Grow your Business @ https://www.coherentmarketinsights.com/insight/buy-now/1971
- By Technique
- Polymerase Chain Reaction
- Cell Cultures
- By Disease Indication
- CNS Infection
- Brain Abscess
- Diarrhoeal Disease
- Enteric/Typhoid Fever
- Respiratory Infections
- Blood Infections
- Infectious Mononucleosis
- By End User
- Diagnostic Centers
- Government Organizations
- By Region
- North America
- Latin America
- Asia Pacific
- Middle East
- CNS Infection
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.
To know more about us, please visit our website – www.coherentmarketinsights.com
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027